Buy GARDASIL 9 40 ug/.5mL Human Papillomavirus 9-valent Vaccine, Recombinant

GARDASIL 9 is a 9-valent HPV vaccine designed to help prevent certain HPV-related conditions. This recombinant vaccine is administered via intramuscular injection and is available in single-dose vials.

Strength

40 ug/.5mL

Pack Size

10 VIAL, SINGLE-DOSE in 1 CARTON (0006-4119-03) / .5 mL in 1 VIAL, SINGLE-DOSE (0006-4119-01)

Manufacturer / TM Owner

Merck Sharp & Dohme LLC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Uses / Indications

GARDASIL 9 is primarily used for the prevention of diseases caused by nine types of human papillomavirus (HPV). These include certain cancers and genital warts. The vaccine is often recommended for individuals to help reduce the risk of HPV-related health issues.

Side Effects

Common effects of GARDASIL 9 may include mild to moderate reactions at the injection site, such as pain, swelling, or redness. Some individuals might also experience temporary symptoms like headache, fatigue, or muscle pain following vaccination.

Precautions & Warnings

GARDASIL 9 should be administered by healthcare professionals. Individuals with a history of severe allergic reactions to any component of the vaccine should avoid it. It is important to discuss any medical conditions or allergies with a healthcare provider before receiving the vaccine.

Avoid Interactions

GARDASIL 9 is generally considered safe, but interactions with other medications or vaccines are not well-documented. It is advisable to inform healthcare providers about all current medications and vaccines before receiving GARDASIL 9.

References

Frequently Asked Questions

GARDASIL 9 is used to help prevent certain diseases caused by nine types of human papillomavirus (HPV), including some cancers and genital warts.

GARDASIL 9 is administered via intramuscular injection, typically in the upper arm or thigh.

Common side effects may include pain, swelling, or redness at the injection site, as well as temporary symptoms like headache, fatigue, or muscle pain.

Individuals with a history of severe allergic reactions to any component of the vaccine should avoid GARDASIL 9. Always consult a healthcare provider for personalized advice.

Interactions with other medications are not well-documented. It is advisable to inform healthcare providers about all current medications before receiving GARDASIL 9.

Published by GNH India Pharmaceuticals Limited

Last updated: 18 May 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.